|
Lonza Group AG / Key word(s): Half Year Results 25-Jul-2024 / 06:55 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Ad hoc announcement pursuant to Art. 53 LR
Group Financial Summary
For more details on performance and financials, please refer to the Half-Year 2024 Presentation, Half-Year 2024 Report and Alternative Performance Measures (APM) 2024 Report. 1 Sales growth figures, expressed as a percentage (%), are at Constant Exchange Rate (CER) About Lonza Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers’ complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com End of Inside Information |
Man-made antibody successfully prevents organ rejection after transplantation
A man-made antibody successfully prevented organ rejection when tested in primates that had undergone a kidney transplant, Duke Health researchers report.
August 30, 2023